Trends in phase III randomized controlled clinical trials on the treatment of advanced non-small-cell lung cancer.

ABSTRACT: The objective of this review was to analyze trends in outcomes and in the quality of phase III randomized controlled trials on advanced NSCLC published between 2000 and 2012, selecting 76 trials from a total of 122 retrieved in a structured search. Over the study period, the number of randomized patients per trial increased by 14 per year (P = 0.178). The sample size significantly increased between 2000 and 2012 in trials of targeted agents (460.1 vs. 740.8 patients, P = 0.009), trials of >1 drug (360.4 vs. 584.8, P = 0.014), and those including patients with good performance status (675.3 vs. 425.6; P = 0.003). Quality of life was assessed in 46 trials (60.5%), and significant improvements were reported in 10 of these (21.7%). Platinum-based regimens were the most frequently investigated

SUBMITTER: Fernandez-Lopez C 

PROVIDER: S-EPMC5055155 | biostudies-literature | 2016 Sep

REPOSITORIES: biostudies-literature